Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer. - Wikidata - awgldk - TriplyDB

Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer.

Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer.

http://www.wikidata.org/entity/Q33514852

about

VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma r84, a novel therapeutic antibody against mouse and human VEGF with potent anti-tumor activity and limited toxicity induction Exogenous administration of protease-resistant, non-matrix-binding IGFBP-2 inhibits tumour growth in a murine model of breast cancer.Vascular channels formed by subpopulations of PECAM1+ melanoma cells.Longitudinal Tracing of Spontaneous Regression and Anti-angiogenic Response of Individual Microadenomas during Colon Tumorigenesis.Elevated Slit2 Activity Impairs VEGF-Induced Angiogenesis and Tumor Neovascularization in EphA2-Deficient Endothelium The proliferation of malignant melanoma cells could be inhibited by ranibizumab via antagonizing VEGF through VEGFR1.GU81, a VEGFR2 antagonist peptoid, enhances the anti-tumor activity of doxorubicin in the murine MMTV-PyMT transgenic model of breast cancer.The VEGF family in cancer and antibody-based strategies for their inhibition.VHL deletion impairs mammary alveologenesis but is not sufficient for mammary tumorigenesis.On-Bead Two-Color (OBTC) Cell Screen for Direct Identification of Highly Selective Cell Surface Receptor Ligands.Generation of a new bioluminescent model for visualisation of mammary tumour development in transgenic mice.MUC4 overexpression augments cell migration and metastasis through EGFR family proteins in triple negative breast cancer cells.Aβ42-binding peptoids as amyloid aggregation inhibitors and detection ligands.Structure and cancer immunotherapy of the B7 family member B7x Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth.A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth.Cycloamylose-nanogel drug delivery system-mediated intratumor silencing of the vascular endothelial growth factor regulates neovascularization in tumor microenvironment Exosomes derived from mesenchymal stem cells suppress angiogenesis by down-regulating VEGF expression in breast cancer cells.Mechanisms controlling the effects of bevacizumab (avastin) on the inhibition of early but not late formed corneal neovascularization.Antiangiogenic Therapy Impedes Infiltration by CD4+ and CD8+ Cells Into an Early Colon Tumor IBC's 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of The Antibody Society, December 5-8, 2011, San Diego, CA.The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies Anti-angiogenic efficacy of 5'-triphosphate siRNA combining VEGF silencing and RIG-I activation in NSCLCs Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer.Myeloid-derived suppressor cells in breast cancer.Down-regulation of PLCγ2-β-catenin pathway promotes activation and expansion of myeloid-derived suppressor cells in cancer.VEGF and pleiotrophin modulate the immune profile of breast cancer.Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer.Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study.Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies.Subsets, expansion and activation of myeloid-derived suppressor cells.Cross-talk between tumor and myeloid cells: how to tip the balance in favor of antitumor immunity.Potential antitumor therapeutic strategies of human amniotic membrane and amniotic fluid-derived stem cells.Modulation of immunity by antiangiogenic molecules in cancer.Deciphering and reversing tumor immune suppression.Role of myeloid-derived suppressor cells in autoimmune disease.Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.The immunobiology of myeloid-derived suppressor cells in cancer.

P2860

Q24618562-2F15100E-64EB-4055-8296-5E16CB43A7ED Q26775769-CB23AF31-42AC-4240-A2D6-772A6E3AAA17 Q27321768-38E9A109-D49D-4048-933E-3FCB12393022 Q30384833-0AB71386-72EE-4481-9BBD-9F58B7DDBADC Q30413784-E6EB84EB-BC91-4ECB-9718-43B6547C426D Q30641075-B6A5DC7D-3274-43D2-BBA2-23FFB357A50E Q30646148-BFF93401-BFD6-44C5-B086-A5B951BBF86D Q33614283-15D0E205-F1F1-4BA4-B10B-F5B1F277BEA5 Q33645920-B08FC79A-4AEA-4BE0-94EF-89AAF53FE1D5 Q33733437-EF4CFFA8-2F48-456B-99CF-FD67EBA655CC Q33816341-9D6FCDEC-3165-4136-BDF7-583847A434DB Q34267615-DDF742E4-7B69-4C2B-A5E8-EC4D261D068E Q34286291-CD8801E9-237E-40ED-88D4-774451A439FE Q34585874-4861A1C3-A281-4035-8E84-F65E10D21EB8 Q34594159-05E9F1E6-BCE3-4284-B60F-44DA403E79FD Q34605921-5E6F6123-7F24-43CC-AADB-A4316EC3AFB3 Q34643612-7AF34BC1-A140-485A-AD8D-A36AC07B0BF5 Q34781478-647297A8-69A4-4456-B8D7-400F0A6CD5D4 Q35052033-FF87F6C6-C5CF-4573-826A-13B20593536D Q35082888-C2569366-6200-4BC1-8F16-42B2FBC94183 Q35143121-4D1772C0-45ED-4C80-847E-B48C4AC0568B Q35820986-53C244E4-C29D-4589-92BD-FCC01F5E551F Q35992493-97D22026-FA71-4308-A518-3E69709AFC31 Q36535465-41EE0B1E-A5AA-4BEC-A3E1-1069A9ED2974 Q36557403-52D61973-EC70-4D71-BBED-4450B1B36407 Q36617328-8357D778-B764-40C4-AD0F-7E68203F3391 Q37172813-43C10FDD-3263-4BE1-84EB-1FDC49C3139A Q37246466-57B639E6-EE20-4F5D-979C-D36E74ACEDD0 Q37328378-8C7C4FB2-2A7A-45DA-9E25-DAAED4D199EB Q37362884-68C938E3-7F44-4443-8D33-CE977BC2CFF8 Q37526782-D85AEDD5-328B-44A9-BE30-9B5A10E8F807 Q37665711-6056DFF9-1B31-4EFA-AC1A-894AA134B21C Q37727050-496A5F1C-8D30-4AC5-8062-A60F2A7D5D7A Q37822746-7B33284D-5421-496A-ACD8-5B2E60620C13 Q38015248-9C8BD174-B667-49FC-ACC0-05D65E33DA6D Q38074154-516C934B-521A-42BF-84BA-390171C06E48 Q38124437-A9656E0C-4272-4086-B94C-F7ADD48C3D67 Q38332567-7B4B5BC9-C31E-40BB-AB69-92675F1064A3 Q38586991-31FF4793-E495-4538-813F-A77549C540B3 Q38649547-25711280-4BA0-4958-A170-6704825EF96B

P2860

Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer.

http://www.wikidata.org/entity/Q33514852

description

2009 nî lūn-bûn

@nan

2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Cytokine levels correlate with ...... mouse models of breast cancer.

@ast

Cytokine levels correlate with ...... mouse models of breast cancer.

@en

Cytokine levels correlate with ...... mouse models of breast cancer.

@nl

type

label

Cytokine levels correlate with ...... mouse models of breast cancer.

@ast

Cytokine levels correlate with ...... mouse models of breast cancer.

@en

Cytokine levels correlate with ...... mouse models of breast cancer.

@nl

prefLabel

Cytokine levels correlate with ...... mouse models of breast cancer.

@ast

Cytokine levels correlate with ...... mouse models of breast cancer.

@en

Cytokine levels correlate with ...... mouse models of breast cancer.

@nl

P1433

Q33514852-2E96E2BB-E782-46A5-84C2-FAC23DBB0C90

P1476

Q33514852-8423CDA7-C685-408C-A6FF-4AB1957CB9D4

P2093

Q33514852-52C811BD-4123-4775-8911-8A8D242E2BF2

Q33514852-5BEFB154-1932-434F-B1E7-7C49BF1A9341

Q33514852-94C7C633-4DA3-487F-8D73-32B8B87DD1EF

Q33514852-CAE212F7-CC03-469A-99C6-D5B023C479B7

Q33514852-FFD64724-0865-4E83-84BD-F4414984EF05

P2860

Q33514852-07D2E662-725B-4D5E-8A7F-DF73379DE062

Q33514852-0A86EABC-5A6D-43E0-A383-DC1A8E19A274

Q33514852-0D614D4C-BE2D-4AAA-A260-EE292FE4EAF1

Q33514852-0D71F760-DAF6-417A-85BE-2550DE7D736E

Q33514852-0E90A7B1-B325-4DCF-A921-32BC3020B913

Q33514852-0F2AE778-2D6A-475E-A994-83C36EC06F68

Q33514852-0FA438EA-58FD-4AB6-A056-8C2AE9FC1F54

Q33514852-113194C8-004C-487A-80F5-192C4E0F0013

Q33514852-1ACC4127-5C02-4822-BAD2-62E4614C1564

Q33514852-1E317B56-EF06-44EE-B279-84CC409F4018

P304

Q33514852-9C9BF096-25CC-4942-A646-F81236BD9BA5

P31

Q33514852-94A6D7A1-92D1-4A9B-ADE4-123BC91D1579

P356

Q33514852-B0BC5A19-0644-4BBB-860D-010267CBE1A2

P407

Q33514852-146E64BE-BA31-425D-BFA7-5F0CCEDE6921

P433

Q33514852-AE60ED8C-FD9E-4157-A9F3-52F9BD6EA5AE

P478

Q33514852-65954200-B351-447E-8F3F-58FD5B45AB71

P50

Q33514852-19165662-7AA7-4E0B-801B-C6A096B92807

P577

Q33514852-614CA1B7-E71B-45B0-9D09-26104C64DFBF

P5875

Q33514852-D110471C-2763-40B8-BC52-F1CDAEDEE524

P698

Q33514852-73FEA398-49E7-48A2-9FEA-0E48FEFC135D

P932

Q33514852-B60A0526-6340-4698-BCA8-96E556EB3351

P356

JOURNAL.PONE.0007669

P1433

P1476

Cytokine levels correlate with ...... mouse models of breast cancer.

@en

P2093

Christina L Roland

http://www.w3.org/2001/XMLSchema#string

D Gomika Udugamasooriya

http://www.w3.org/2001/XMLSchema#string

Jason E Toombs

http://www.w3.org/2001/XMLSchema#string

Kristi D Lynn

http://www.w3.org/2001/XMLSchema#string

Rolf A Brekken

http://www.w3.org/2001/XMLSchema#string

P2860

The Hallmarks of Cancer

Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)

Inflammation and cancer

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Inflammation and cancer: back to Virchow?

Myeloid-derived suppressor cells as regulators of the immune system

Differential effects of interleukin-1 alpha and beta on interleukin-6 and chemokine synthesis in neurones

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

Angiogenesis in cancer, vascular, rheumatoid and other disease

The role of myeloid cells in the promotion of tumour angiogenesis

P304

e7669

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0007669

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-11-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38066216

http://www.w3.org/2001/XMLSchema#string

P698

19888452

http://www.w3.org/2001/XMLSchema#string

P932

2766251

http://www.w3.org/2001/XMLSchema#string